Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6498
    +0.0009 (+0.13%)
     

  • OIL

    82.89
    -0.47 (-0.56%)
     

  • GOLD

    2,331.10
    -11.00 (-0.47%)
     

  • Bitcoin AUD

    98,368.80
    -3,442.56 (-3.38%)
     

  • CMC Crypto 200

    1,385.80
    -38.30 (-2.69%)
     

  • AUD/EUR

    0.6072
    +0.0015 (+0.25%)
     

  • AUD/NZD

    1.0948
    +0.0017 (+0.16%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Why ChemoCentryx Stock Tanked in 2021

George Budwell, The Motley Fool
·2-min read
Why ChemoCentryx Stock Tanked in 2021

Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

Continue reading